ROCHE : TITULO OFICIAL DEL ENSAYO CLÍNICO IMFORTE :
A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF LURBINECTEDIN IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH ATEZOLIZUMAB AS MAINTENANCE THERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CÁNCER ( ES-SCLC ) FOLLOWING FIRST-LINE INDUCTION THERAPY WITH CARBOPLATIN, ETOPÓSIDE AND ATEZOLIZUMAB .